Skip to content

post-stroke aphasia treatment

Establishment of post-stroke aphasia treatment (rLANG) by personalized speech therapy using repetitive magnetic stimulation (rTMS) with brain activity navigation system and a language support application (KOTOREHA) - combination treatment of rTMS and support application

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs042250044
Enrollment
26
Registered
2025-06-12
Start date
2025-06-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who have aphasia (including apraxia of speech) after a stroke stroke

Interventions

combination therapy of repetitive Transcranial Magnetic Stimulation (rTMS) and speach application (KOHOREHA)
stroke rehabilitation

Sponsors

Ueki Yoshino
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients who have had a stroke for more than 6 months (2) Age 18 years or older (3) Adult patients who have developed aphasia after a stroke and include the following criteria (3)-1 Aphasic patients who can take the WAB aphasia test (4) Patients who can give written consent themselves. *If the subject is fully capable of consenting but has difficulty writing due to paralysis or aphasia, written consent will be obtained from a proxy writer after confirming the subject's consent. *If it is objectively determined that the research subject's comprehension is insufficient due to aphasia, etc., written consent will be obtained from the proxy as well as the subject himself/herself. (5) Patients who have not had a seizure for at least one year prior to participating in the clinical research study

Exclusion criteria

Exclusion criteria: (1) Patients for whom TMS or MRI is difficult to perform. Examples include the following: (1)-1 Severe heart disease (1)-2 Poorly controlled hypertension (1)-3 Pulmonary embolism, acute cor pulmonale, or severe pulmonary hypertension within 90 days prior to the start of the study (1)-4 Severe liver or kidney dysfunction (1)-5 Severe orthopedic disease that prevents exercise (1)-6 Severe cognitive impairment or severe psychiatric illness (1)-7 Patients who cannot wear a headset or powered orthosis (1)-8 Patients using a pacemaker or implantable cardioverter defibrillator (1)-9 Patients with an indwelling catheter in the heart (1)-10 Patients with significant pain at the attachment site (1)-11 Patients with a fever (1)-12 Patients with skin sensory disorders (1)-13 Patients with metal such as clips in the skull (1)-14 Patients with clearly elevated intracranial pressure (1)-15 Patients with malignant tumors or tuberculous diseases (1)-16 Patients with severe spasticity or contracture (1)-17 Pregnant women (2) Patients with a history of dementia (3) Patients with moderate to severe visual impairments who have difficulty recognizing the application (4) Patients with moderate to severe hearing impairments who have difficulty recognizing the voice of the application (5) Patients with moderate to severe higher brain dysfunctions who have difficulty operating or executing the application (6) Patients who are deemed inappropriate for participation in this study by a physician

Design outcomes

Primary

MeasureTime frame
Change from the baseline in the total score of the Aphasia Quotient (AQ) items of the Western Aphasia Battery (WAB)

Secondary

MeasureTime frame
(1) Standard Language Test of Aphasia (SLTA) Sub-test names (2) Supplementary Tests for Standard Language Test of Aphasia (SLTA-ST) Names (3) Trail Making Test Japanese version (TMT-J) (4) Raven's Colored Progressive Materices (RCPM) (5) Visual Analogue Scale (VAS) (6) Magnetic Resonance Imaging (MRI)

Contacts

Public ContactYuta Katsuno

Nagoya city university Mirai kosei hospital

katsuno2@med.nagoya-cu.ac.jp+81-52-704-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026